Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emicizumab

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

- PMLiVE

SMC fails to recommend Roche’s Perjeta

Says drug is not a cost-effective option in breast cancer

Shire Basingstoke

Shire drawn into Luxembourg tax haven exposé

Firm is one of 340 companies identified in report by ICIJ

Roche - Basel

Roche invests in diagnostics in China

Commits 450m Swiss francs to manufacturing facility

Biogen Idec building

EMA starts review of Biogen Idec’s haemophilia A therapy

Elocta already on the market in the US, Canada and Australia

- PMLiVE

AbbVie is not looking at another big acquisition, says CEO

Unlikely to consider another deal on the scale of failed Shire merger

- PMLiVE

Roche outlines $3bn expansion for its Basel site

Decade-long programme will see the Swiss pharma company boost its presence in its home city

- PMLiVE

Pressure put on Roche to cut Kadcyla’s UK price

30,000 people sign petition to help make the breast cancer drug available on the NHS

- PMLiVE

AbbVie and Shire bring merger plans to a close

Blames tax changes in the US

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

- PMLiVE

AbbVie board recommends dropping Shire deal

Tells stakeholders to vote against merger in light of new rules on corporate tax

- PMLiVE

AbbVie rethinks Shire merger in light of US tax crackdown

Follows action to discourage 'inversion deals' aimed at reducing corporate tax rates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links